Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Reforming China's drug regulatory system

Nature Reviews Drug Discovery volume 17, pages 858–859 (2018)Cite this article

Subjects

Phase 1: creating an efficient process

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Timeline of China's drug regulatory system reform.

Author information

Authors and Affiliations

  1. Fudan Center for Study of Pharmaceuticals and Healthcare Strategy, Pudong, Shanghai, China

    Lili Xu & Liming Shao

  2. Shanghai Association of Food and Drug Safety, Xuhui, Shanghai, China

    Huijun Gao

  3. Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, MA, USA

    Kenneth I. Kaitin

Authors
  1. Lili Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Huijun Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenneth I. Kaitin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Liming Shao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Liming Shao.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information

China's drug regulatory system reform timeline (May 2015 to May 2018)* (PDF 108 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, L., Gao, H., Kaitin, K. et al. Reforming China's drug regulatory system. Nat Rev Drug Discov 17, 858–859 (2018). https://doi.org/10.1038/nrd.2018.150

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2018.150

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research